NasdaqCM:BLPH

Stock Analysis Report

Executive Summary

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States.

Snowflake

Fundamentals

Flawless balance sheet and fair value.

Share Price & News

How has Bellerophon Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.1%

BLPH

0.5%

US Medical Equipment

-0.02%

US Market


1 Year Return

-50.6%

BLPH

9.9%

US Medical Equipment

1.6%

US Market

BLPH underperformed the Medical Equipment industry which returned 9.9% over the past year.

BLPH underperformed the Market in United States of America which returned 1.6% over the past year.


Share holder returns

BLPHIndustryMarket
7 Day-1.1%0.5%-0.02%
30 Day-9.0%0.09%2.7%
90 Day-10.9%2.0%1.4%
1 Year-50.6%-50.6%10.8%9.9%3.8%1.6%
3 Year-60.8%-60.8%69.0%63.9%45.2%35.8%
5 Yearn/a136.2%109.3%61.8%44.1%

Price Volatility Vs. Market

How volatile is Bellerophon Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bellerophon Therapeutics undervalued based on future cash flows and its price relative to the stock market?

6.86x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Bellerophon Therapeutics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Bellerophon Therapeutics to establish if it is available at substantial discount.


Price Based on Earnings

Bellerophon Therapeutics is good value based on earnings compared to the US Medical Equipment industry average.

Bellerophon Therapeutics is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

Bellerophon Therapeutics is poor value based on expected growth next year.


Price Based on Value of Assets

Bellerophon Therapeutics is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Bellerophon Therapeutics expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

3.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Bellerophon Therapeutics is high growth as no revenue estimate data is available.

Bellerophon Therapeutics's earnings are expected to grow by 3.6% yearly, however this is not considered high growth (20% yearly).

Unable to compare Bellerophon Therapeutics's revenue growth to the United States of America market average as no estimate data is available.

Bellerophon Therapeutics's earnings growth is positive but not above the United States of America market average.

Bellerophon Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Bellerophon Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Bellerophon Therapeutics performed over the past 5 years?

31.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Bellerophon Therapeutics has delivered over 20% year on year earnings growth in the past 5 years.

Bellerophon Therapeutics has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

Bellerophon Therapeutics has become profitable in the last year making it difficult to compare the US Medical Equipment industry average.


Return on Equity

Bellerophon Therapeutics made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).


Return on Assets

Bellerophon Therapeutics used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

It is difficult to establish if Bellerophon Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Bellerophon Therapeutics's financial position?


Financial Position Analysis

Bellerophon Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Bellerophon Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Bellerophon Therapeutics has no debt.

Bellerophon Therapeutics has not taken on any debt in the past 5 years.

Bellerophon Therapeutics has no debt, it does not need to be covered by operating cash flow.

Bellerophon Therapeutics has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

Bellerophon Therapeutics has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is Bellerophon Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Bellerophon Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Bellerophon Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Bellerophon Therapeutics has not reported any payouts.

Unable to verify if Bellerophon Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Bellerophon Therapeutics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Bellerophon Therapeutics's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Fabian Tenenbaum (45yo)

2.8yrs

Tenure

US$2,316,905

Compensation

Mr. Fabian Tenenbaum, M.B.A, has been the Chief Executive Officer of Bellerophon Therapeutics, Inc. since November 2016. Mr. Tenenbaum served as Chief Financial Officer and Chief Business Officer of Beller ...


CEO Compensation Analysis

Fabian's remuneration is higher than average for companies of similar size in United States of America.

Fabian's compensation has increased in line with Bellerophon Therapeutics recently becoming profitable.


Management Age and Tenure

2.8yrs

Average Tenure

46yo

Average Age

The tenure for the Bellerophon Therapeutics management team is about average.


Board Age and Tenure

3.6yrs

Average Tenure

52yo

Average Age

The tenure for the Bellerophon Therapeutics board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$31,90514 Jun 19
Theodore Wang
EntityIndividual
Role
Member of the Board of Directors
Director
Shares50,000
Max PriceUS$0.64
BuyUS$16,53324 May 19
Theodore Wang
EntityIndividual
Role
Member of the Board of Directors
Director
Shares27,500
Max PriceUS$0.60
BuyUS$12,19822 May 19
Jonathan Peacock
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares20,000
Max PriceUS$0.61
BuyUS$26,37122 May 19
Theodore Wang
EntityIndividual
Role
Member of the Board of Directors
Director
Shares43,280
Max PriceUS$0.61
BuyUS$2,97522 May 19
Fabian Tenenbaum
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares5,000
Max PriceUS$0.59
BuyUS$100,00014 Mar 19
VR Adviser, LLC
EntityCompany
Shares142,857
Max PriceUS$0.70
BuyUS$500,00025 Jan 19
Jonathan Peacock
EntityIndividual
Role
Chairman of the Board
Chairman of the Board
Shares714,286
Max PriceUS$0.70
BuyUS$315,00025 Jan 19
Theodore Wang
EntityIndividual
Role
Member of the Board of Directors
Director
Shares450,000
Max PriceUS$0.70
BuyUS$400,00025 Jan 19
Naseem Amin
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares571,429
Max PriceUS$0.70

Ownership Breakdown


Management Team

  • Fabian Tenenbaum (45yo)

    CEO & Director

    • Tenure: 2.8yrs
    • Compensation: US$2.32m
  • Peter Fernandes (64yo)

    Chief Regulatory & Safety Officer

    • Tenure: 4.3yrs
    • Compensation: US$693.08k
  • Amy Edmonds (47yo)

    Vice President of Clinical Operations & Administration

    • Tenure: 4yrs
  • Assaf Korner (41yo)

    CFO & Secretary

    • Tenure: 1.7yrs
    • Compensation: US$606.96k
  • Hunter Gillies

    Acting Chief Medical Officer

    • Tenure: 0.9yrs

Board Members

  • Naseem Amin (57yo)

    Independent Director

    • Tenure: 4.3yrs
    • Compensation: US$110.00k
  • Matt Bennett (48yo)

    Director

    • Tenure: 1.5yrs
    • Compensation: US$95.00k
  • Mary Cloyd (64yo)

    Independent Director

    • Tenure: 3.6yrs
    • Compensation: US$115.00k
  • Fabian Tenenbaum (45yo)

    CEO & Director

    • Tenure: 2.8yrs
    • Compensation: US$2.32m
  • Scott Bruder (57yo)

    Independent Director

    • Tenure: 4.3yrs
    • Compensation: US$100.00k
  • Jon Peacock (61yo)

    Chairman of the Board

    • Tenure: 5.3yrs
    • Compensation: US$200.00k
  • Andre Moura (37yo)

    Independent Director

    • Tenure: 5.6yrs
    • Compensation: US$105.00k
  • Ted Wang (52yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: US$100.00k
  • Crispin Teufel (43yo)

    Director

    • Tenure: 0.5yrs

Company Information

Bellerophon Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bellerophon Therapeutics, Inc.
  • Ticker: BLPH
  • Exchange: NasdaqCM
  • Founded: 2009
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$40.207m
  • Shares outstanding: 68.91m
  • Website: https://www.bellerophon.com

Number of Employees


Location

  • Bellerophon Therapeutics, Inc.
  • 184 Liberty Corner Road
  • Suite 302
  • Warren
  • New Jersey
  • 7059
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BLPHNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2015
6L7DB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2015

Biography

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpul ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 01:16
End of Day Share Price2019/09/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.